Acute lymphoblastic leukemia (ALL) is the major neoplasia type among children. Despite the tremendous success of current treatment strategies, drug resistance still remains a major cause of chemotherapy failure and relapse in pediatric patients. Overwhelming evidence illustrates that microRNAs (miRNAs) act as post-transcriptional regulators of drug-resistance-related genes. The current study was aimed at how dysregulated miRNA-mRNA-signaling pathway interaction networks mediate resistance to four commonly used chemotherapy agents in pediatric ALL, including asparaginase, daunorubicin, prednisolone, and vincristine. Using public expression microarray datasets, a holistic in silico approach was utilized to investigate candidate drug resistanc...
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall sur...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
SummaryAcute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of ...
Abstract Background Acute lymphoblastic leukemia is the most prevalent neoplasia among children. Des...
<div><p>Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is freq...
textabstractBackground MicroRNA regulate the activity of protein-coding genes including those involv...
MicroRNAs (miRNAs) regulate the expression of protein-coding genes and represent potential biomarker...
The pediatric T cell acute lymphoblastic leukemia (T-ALL) still remains a cancer with worst prognosi...
Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is frequent. Th...
Dysregulation of microRNA (miRNA) expression contributes to the pathogenesis of several clinical con...
Refractory disease and relapse remain the main causes of cancer therapy failure. Refined risk strati...
Copyright © 2014 Muhterem Duyu et al. This is an open access article distributed under the Creative ...
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric neoplasia. Highly heterogene...
Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regu...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy originating from T-cell prec...
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall sur...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
SummaryAcute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of ...
Abstract Background Acute lymphoblastic leukemia is the most prevalent neoplasia among children. Des...
<div><p>Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is freq...
textabstractBackground MicroRNA regulate the activity of protein-coding genes including those involv...
MicroRNAs (miRNAs) regulate the expression of protein-coding genes and represent potential biomarker...
The pediatric T cell acute lymphoblastic leukemia (T-ALL) still remains a cancer with worst prognosi...
Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is frequent. Th...
Dysregulation of microRNA (miRNA) expression contributes to the pathogenesis of several clinical con...
Refractory disease and relapse remain the main causes of cancer therapy failure. Refined risk strati...
Copyright © 2014 Muhterem Duyu et al. This is an open access article distributed under the Creative ...
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric neoplasia. Highly heterogene...
Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regu...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy originating from T-cell prec...
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall sur...
Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Alt...
SummaryAcute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of ...